

Medicine

## Human Crisis in Facing Emerging Fatal Pathogenic Microbes The Hidden Obstacles

**Morihito Ishida\***

Kyoto University, Yoshidahonmachi, Sakyo Ward, Kyoto, 606-8501, Japan

\*: All correspondence should be sent to: Dr. Morihito Ishida

Author's Contact: Dr. Morihito Ishida, M.D., Ph.D., E-mail: [morihito\\_ishida1@hotmail.com](mailto:morihito_ishida1@hotmail.com)

DOI: <https://doi.org/10.15354/si.24.co211>

Funding: No funding source declared.

COI: The author declares no competing interest.


AI Declaration: The author affirms that artificial intelligence did not contribute to the process of preparing the work.

The emergence of new and increasingly fatal pathogens presents significant challenges to global public health systems, and the intersection of human health and pathogenic microbes is a swiftly evolving area of concern. Continuous vigilance and preparedness in the presence of emergent infectious threats are underscored by the rapid spread of diseases such as COVID-19, Ebola, and Zika virus. Nevertheless, the effective battle against these fatal pathogens is significantly impeded by concealed obstacles, including misinformation/miscommunication, inadequate healthcare infrastructure in developing countries, and lack of funding for research, etc. A multifaceted approach is necessary to overcome these obstacles, which includes enhanced surveillance systems, public education campaigns on preventive measures, increased investment in research and development, and global collaboration to ensure the timely detection and response to emerging threats. We can only hope to mitigate the impact of fatal pathogenic microbes on human health and prevent future crises from unfolding by making a concerted effort to surmount these hidden obstacles.

**Keywords:** Emerging Fatal Pathogens; Microbes; Human Being; Obstacles; Crisis

Science Insights, 2024 August 31; Vol. 45, No. 2, pp.1457-1459.

© 2024 Insights Publisher. All rights reserved.



Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the [Creative Commons Attribution-NonCommercial 4.0 License](https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed by the Insights Publisher.

**I**N RECENT YEARS, the world has experienced the emergence of numerous fatal pathogenic microbes that have resulted in pervasive devastation and loss of life. These microbes, including the novel coronavirus (COVID-19) and the lethal Ebola virus, have posed a challenge to our healthcare systems and underscored the necessity of being prepared for future epidemics or pandemics (1, 2). The current inquiry is whether we are prepared for the potential arrival of the next

emergent fatal pathogenic microbes.

The absence of effective surveillance and monitoring systems is one of the primary obstacles to managing emergent pathogenic microbes (3, 4). Numerous nations worldwide lack the infrastructure and resources necessary to promptly identify and address emerging infectious diseases. This can result in the disease's uncontrolled spread, as control measures are delayed.

Additionally, the rapid globalization of commerce and

travel has facilitated the transmission of infectious diseases across borders (5, 6). The interconnectedness of our world makes it challenging to contain and control a novel pathogen, as it can rapidly spread from one country to another. This poses a substantial obstacle to the coordination of international responses to outbreaks.

The absence of investment in the research and development of new treatments and vaccines is another issue that impedes our preparedness for emergent pathogenic microbes (7). Numerous infectious diseases lack effective treatments or preventative measures, rendering us susceptible to their effects. A lack of investment in this critical public health sector has resulted from the high costs and risks associated with the development of novel drugs and vaccines.

The escalation of antimicrobial resistance poses a significant hazard to our capacity to combat infectious diseases (8). The emergence of superbugs that are resistant to a wide range of commonly used pharmaceuticals has been facilitated by the misuse and overuse of antibiotics. This can exacerbate the risk of severe illness and mortality and complicate the treatment of infections.

Furthermore, our healthcare systems are frequently inadequately prepared to address outbreaks of emergent pathogens (9, 10). Clinics and hospitals may be unable to diagnose and treat patients with rare infectious diseases due to a lack of resources and expertise. This can result in the outbreak's impact being further exacerbated by the delays in providing care to those who require it most.

The absence of public education and awareness regarding infectious diseases can facilitate the transmission of pathogens (11). The implementation of effective control measures can be

challenging for authorities due to the distress and confusion that can result from misinformation and misconceptions regarding the nature of infectious diseases. Raising awareness of the risks of emerging pathogens and advocating for preventive measures necessitates public outreach and education campaigns (12).

Another obstacle in managing emergent pathogenic microbes is the absence of coordination and communication among a variety of stakeholders. Governments, healthcare providers, researchers, and international organizations must collaborate to ensure that information and resources are shared in a timely manner (13-15). Failure to do so may result in the creation of voids in the response effort and impede our capacity to contain the outbreak.

The socio-economic consequences of emergent infectious diseases can be catastrophic. New pathogen outbreaks have the potential to cause social unrest, overburden healthcare systems, and disrupt economies (16, 17). These epidemics frequently disproportionately affect the most vulnerable populations, including the impoverished and marginalized, thereby exacerbating health disparities.

Therefore, in order to effectively respond to the next emergent fatal pathogenic microbes, there are still numerous challenges that must be addressed, despite the significant progress made in our understanding and control of infectious diseases. Investing in research and development, promoting public awareness and education, strengthening international collaboration, and enhancing surveillance and monitoring systems are all essential components of preparedness efforts. It is imperative that we take proactive measures to prepare for any future challenges that may arise by incorporating the lessons learned from previous outbreaks. ■

## References

1. Okesanya OJ, Olatunji G, Manirambona E, Oluebube MM, Rasheed AA, Olaleke NO, Ogunlayi AC, Ogaya JB, Oladipo EK, Igbalajobi OA, Oso TA, Lucero-Prisno DE III. Synergistic fight against future pandemics: Lessons from previous pandemics. *Infez Med* 2023; 31(4):429-439. DOI: <https://doi.org/10.53854/liim-3104-2>
2. Mishra B, Rath S, Mohanty M, Mohapatra PR. The threat of impending pandemics: A proactive approach. *Cureus* 2023; 15(3):e36723. DOI: <https://doi.org/10.7759/cureus.36723>
3. Institute of Medicine (US) Forum on Emerging Infections; Davis JR, editor. *Managed Care Systems and Emerging Infections: Challenges and Opportunities for Strengthening Surveillance, Research, and Prevention: Workshop Summary*. Washington (DC): National Academies Press (US); 2000. 4, Surveillance and Monitoring. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK100180/>
4. Nsubuga P, White ME, Thacker SB, et al. *Public Health Surveillance: A Tool for Targeting and Monitoring Interventions*. In: Jamison DT, Breman JG, Measham AR, et al., editors. *Disease Control Priorities in Developing Countries*. 2nd edition. Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2006. Chapter 53. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK11770/>
5. Findlater A, Bogoch II. Human mobility and the global spread of infectious diseases: A focus on air travel. *Trends Parasitol* 2018; 34(9):772-783. DOI: <https://doi.org/10.1016/j.pt.2018.07.004>
6. Selvanathan EA, Jayasinghe M, Selvanathan S. International tourism and infectious disease transmission nexus: A cross-country and regional study. *J Trav Res* 2022; 61(8):1910-1927. DOI: <https://doi.org/10.1177/00472875211048932>
7. Hoffman M. Global pandemic preparedness report reveals lack of investment in therapeutics and vaccines. *Health Policy Watch-Independent Global Health Reporting*, January 24, 2024. Last access:

July 04, 2024. Available at:

<https://healthpolicy-watch.news/global-pandemic-preparedness-report-reveals-lack-of-investment-in-therapeutics-and-vaccines/>

8. Salam MA, Al-Amin MY, Salam MT, Pawar JS, Akhter N, Rabaan AA, Alqumber MAA. Antimicrobial resistance: A growing serious threat for global public health. *Healthcare (Basel)* 2023; 11(13):1946. DOI: <https://doi.org/10.3390/healthcare11131946>
9. Filip R, Gheorghita Puscaselu R, Anchidin-Norocel L, Dimian M, Savage WK. Global challenges to public health care systems during the COVID-19 pandemic: A review of pandemic measures and problems. *J Pers Med* 2022; 12(8):1295. DOI: <https://doi.org/10.3390/jpm12081295>
10. Frieden TR, Lee CT, Lamorde M, Nielsen M, McClelland A, Tangcharoensathien V. The road to achieving epidemic-ready primary health care. *Lancet Public Health*. 2023; 8(5):e383-e390. DOI: [https://doi.org/10.1016/S2468-2667\(23\)00060-9](https://doi.org/10.1016/S2468-2667(23)00060-9)
11. Sabin NS, Calliope AS, Simpson SV, Arima H, Ito H, Nishimura T, Yamamoto T. Implications of human activities for (re)emerging infectious diseases, including COVID-19. *J Physiol Anthropol* 2020; 39(1):29. DOI: <https://doi.org/10.1186/s40101-020-00239-5>
12. Madhumathi J, Sinha R, Veeraraghavan B, Walia K. Use of "social media"-An option for spreading awareness in infection prevention. *Curr Treat Options Infect Dis* 2021; 13(1):14-31. DOI: <https://doi.org/10.1007/s40506-020-00244-3>
13. Hayes SL, Mann MK, Morgan FM, Kelly MJ, Weightman AL. Collaboration between local health and local government agencies for health improvement. *Cochrane Database Syst Rev* 2012; 10(10):CD007825. DOI: <https://doi.org/10.1002/14651858.CD007825.pub6>
14. Belrhiti Z, Bigdeli M, Lakhali A, Kaoutar D, Zbiri S, Belabbes S. Unravelling collaborative governance dynamics within healthcare networks: A scoping review. *Health Policy Plan* 2024; 39(4):412-428. DOI: <https://doi.org/10.1093/heapol/czae005>
15. Alderwick H, Hutchings A, Briggs A, Mays N. The impacts of collaboration between local health care and non-health care organizations and factors shaping how they work: A systematic review of reviews. *BMC Public Health* 2021; 21(1):753. DOI: <https://doi.org/10.1186/s12889-021-10630-1>
16. Barach P, Fisher SD, Adams MJ, Burstein GR, Brophy PD, Kuo DZ, Lipshultz SE. Disruption of healthcare: Will the COVID pandemic worsen non-COVID outcomes and disease outbreaks? *Prog Pediatr Cardiol* 2020; 59:101254. DOI: <https://doi.org/10.1016/j.ppedcard.2020.101254>
17. Samsudin EZ, Yasin SM, Ruslan NH, Abdullah NN, Noor AFA, Hair AFA. Socioeconomic impacts of airborne and droplet-borne infectious diseases on industries: A systematic review. *BMC Infect Dis* 2024; 24(1):93. DOI: <https://doi.org/10.1186/s12879-024-08993-y>

---

Received: June 28, 2024 | Revised: July 11, 2024 | Accepted: July 17, 2024

---